Improving treatment for ovarian cancer that resists standard therapies
Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer
This study is testing a new treatment for advanced ovarian cancer in patients who haven't responded to regular therapies, using a special medicine that targets cancer cells with tiny radioactive particles to help destroy them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11081781 on NIH RePORTER |
What this research studies
This research focuses on advanced ovarian cancer, particularly in patients who have developed resistance to standard treatments using PARP inhibitors. The approach involves using a novel theranostic radiopharmaceutical therapy that combines a small molecule similar to an existing drug with radioactive particles to target cancer cells directly. By delivering cytotoxic alpha particles to the nucleus of resistant cancer cells, the goal is to create lethal DNA damage that can overcome treatment resistance. The research will utilize mouse models to assess the effectiveness and safety of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with advanced ovarian cancer who have shown resistance to PARP inhibitors.
Not a fit: Patients with early-stage ovarian cancer or those who have not been treated with PARP inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for women with advanced ovarian cancer who have become resistant to current therapies.
How similar studies have performed: While the approach of using theranostic radiopharmaceuticals is innovative, similar strategies have shown promise in other cancers, indicating potential for success in this area.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Farwell, Michael David — University of Pennsylvania
- Study coordinator: Farwell, Michael David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.